Tartis Inc Profile last edited on: 5/29/14
CAGE: 5DSB3
UEI:
Business Identifier: anti-cancer and anti-aging drugs 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 26
County: Erie
Congr. District: 26
County: Erie
Public Profile
Tartis, Inc. is a discovery stage biotechnology company working on the development of novel anti-cancer and anti-aging drugs. The firm's core, proprietary technology is licensed from the laboratories of Professor Gudkov from Roswell Park Cancer Institute (Buffalo, NY). Tartis, Inc. pipeline includes lead compounds for treatment of breast and prostate cancers, melanoma and hematological malignancies, as well as leads and drug candidates for delaying the development of age-related diseases (including cancer) and prolonging human life.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2010 | 1 | NIH | $107,428 | |
| Project Title: New Type Of Androgen Receptor Inhibitors For Prostate Cancer Treatment | ||||
| 2010 | 1 | NIH | $112,885 | |
| Project Title: Novel Hematopoietic Conditioning Agents For Treatment Of Hematological Diseases | ||||
Key People / Management
l Brownlee
Catherine A Burkhart
Olga B Chernova
Catherine A Burkhart
Olga B Chernova
